Northwestern University Human Resources

Calidi Biotherapeutics announces FDA clearance for CLD-101, a novel stem-cell based oncolytic virus delivery platform for high-grade glioma, with a Phase 1b/2 trial expected to start in late 2024.

Maryann Webb's fight with Clostridioides difficile and breast cancer drives her advocacy for fecal microbiota transplants and classifying C diff as a notifiable disease. New research links mild COVID-19 to long-term cognitive deficits. A survey shows low vaccination rates for flu, COVID-19, RSV, and pneumococcal disease. Georgia reduced chronic hepatitis C infections by 67% through state-CDC collaboration. Tina Tan emphasizes education and global collaboration to address antimicrobial resistance.

FDA approves Cobenfy, a new schizophrenia treatment combining xanomeline and trospium chloride, targeting cholinergic receptors, offering a new alternative to traditional antipsychotics.

AI enhances multi-omics analysis for NSCLC treatment, aiding early detection, biomarker discovery, and targeted therapy. AI in medicine includes rule-based and machine learning approaches, with deep learning improving diagnostics. Challenges include high costs and data privacy concerns.

Johns Hopkins University ranked No. 6 in the U.S. News & World Report's national universities list, tied with Caltech, Duke, and Northwestern. Hopkins has been in the top 10 since 2019 and top 20 since the 1980s rankings began. The university also ranked No. 1 in biomedical engineering, No. 5 in biocomputer/bioinformatics/biotechnology, and No. 18 in artificial intelligence among undergraduate programs.

Researchers at Johns Hopkins Kimmel Cancer Center found MYC gene activation initiates prostate cancer, initially attracting immune cells but later evading them, suggesting MYC as a therapeutic target.

Cancer patients seek early financial advice; FDA expands Keytruda approval; overweight/obese patients at higher risk for second cancers; novel three-drug regimen shows 80% response rate; patritumab deruxtecan meets progression-free survival endpoint; Oncternal terminates clinical trials; Ultimovacs halts enrollment; bipartisan Senate bill targets misleading drug ads; Trojan condoms face lawsuit over 'forever chemicals'; Ossium Health achieves first successful stem-cell transplant; higher incarceration rates linked to cancer mortality; FDA issues guidance on multiregional cancer trials.

Researchers at Johns Hopkins Kimmel Cancer Center found MYC gene activation initiates and progresses prostate cancer, initially attracting immune cells but later hiding the tumor. This discovery could lead to new therapeutic targets.

Northwestern University researchers linked specific SCN2A gene mutations to epilepsy or autism in young children, establishing a direct link between variant and disease severity for more precise diagnosis and treatment.

Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and leadership. He is currently a Senior Advisor at Frazier Healthcare Partners and has held senior roles at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, and Genzyme Corporation. Dr. Vasconcelles expressed enthusiasm for Kura's precision oncology approach and its menin inhibitor program for acute leukemias.